These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34711626)

  • 1. Case of postural urticaria in a 14-year-old girl.
    Gabrielli S; Le M; Netchiporouk E; Ben-Shoshan M
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34711626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria.
    Kaur S; Jabbal IS; Bhasin AK
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35850790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
    He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
    Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
    Abe N; Bohgaki M; Kasahara H
    Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in Chronic Urticaria: An Italian Survey.
    Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
    Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab.
    Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A
    Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic inducible urticaria: A systematic review of treatment options.
    Dressler C; Werner RN; Eisert L; Zuberbier T; Nast A; Maurer M
    J Allergy Clin Immunol; 2018 May; 141(5):1726-1734. PubMed ID: 29438771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
    Maurer M; Zuberbier T; Metz M
    Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
    Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 16. "Chronic Urticaria": Recommendations From an Allergist and Immunologist.
    Awosika O; Qureshi A; Ehrlich A; Fonacier L
    Dermatitis; 2018; 29(5):292-293. PubMed ID: 30179970
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    Sánchez J; Zakzuk J; Cardona R
    J Allergy Clin Immunol Pract; 2018; 6(1):177-182.e1. PubMed ID: 28709817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria.
    Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.